tiprankstipranks
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
US Market

Intra-Cellular Therapies (ITCI) Income Statement

Compare
918 Followers

Intra-Cellular Therapies Income Statement

Last quarter (Q3 2024), Intra-Cellular Therapies's total revenue was $175.16M, an increase of 39.23% from the same quarter last year. In Q3, Intra-Cellular Therapies's net income was $-26.32M. See Intra-Cellular Therapies’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 464.37M$ 249.13M$ 81.71M$ 22.53M$ 60.61K
Gross Profit
$ 430.63M$ 228.69M$ 73.67M$ 20.64M$ -416.51K
Operating Expenses
$ 590.01M$ 492.31M$ 359.36M$ 251.86M$ 154.07M
Depreciation and Amortization
$ 528.00K$ 656.00K$ 533.36K$ 528.12K$ 477.12K
EBITDA
$ -158.85M$ -262.97M$ -285.15M$ -230.70M$ -153.53M
Operating Income
$ -159.38M$ -263.63M$ -285.69M$ -231.23M$ -154.01M
Other Income/Expenses
$ 20.34M$ 7.38M$ 1.57M$ 4.24M$ 6.29M
Pretax Income
$ -139.04M$ -256.25M$ -284.12M$ -226.99M$ -147.72M
Net Income
$ -139.67M$ -256.26M$ -284.13M$ -227.01M$ -147.72M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.46$ -2.72$ -3.50$ -3.23$ -2.68
Diluted EPS
$ -1.46$ -2.72$ -3.50$ -3.23$ -2.68
Weighted Average Shares Outstanding
95.88M 94.05M 81.25M 70.36M 55.19M
Weighted Average Shares Outstanding (Diluted)
95.88M 94.05M 81.25M 70.36M 55.19M
Currency in USD

Intra-Cellular Therapies Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis